Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs

[1] Compston A(2002)Multiple sclerosis Lancet 359 1221-1231

[2] Coles A(2013)Clinical and demographic factors affecting disease severity in patients with multiple sclerosis Iran J Neurol 12 1-8

[3] Baghizadeh S(2010)Heterogeneity in multiple sclerosis: scratching the surface of a complex disease Autoimmune Dis 2011 932351-966

[4] Sahraian MA(2015)Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials Eur J Neurol 22 960-S84

[5] Beladimoghadam N(2014)Beyond comorbidity: expanding the definition and measurement of complexity among older adults using administrative claims data Med Care 52 S75-1577

[6] Disanto G(2013)Development and validation of a claims-based prediction model for COPD severity Respir med 107 1568-1300

[7] Berlanga AJ(2015)Developing a stroke severity index based on administrative data was feasible using data mining techniques J Clin Epidemiol 68 1292-1656

[8] Handel AE(2013)Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis Curr med res Opin 29 1647-1471

[9] Para AE(2014)Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study PLoS One 9 e88472-1039

[10] Burrell AM(2014)Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis Curr med res Opin 30 1461-471

[1] Compston A(2002)Multiple sclerosis Lancet 359 1221-1231

[2] Coles A(2013)Clinical and demographic factors affecting disease severity in patients with multiple sclerosis Iran J Neurol 12 1-8

[3] Baghizadeh S(2010)Heterogeneity in multiple sclerosis: scratching the surface of a complex disease Autoimmune Dis 2011 932351-966

[4] Sahraian MA(2015)Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials Eur J Neurol 22 960-S84

[5] Beladimoghadam N(2014)Beyond comorbidity: expanding the definition and measurement of complexity among older adults using administrative claims data Med Care 52 S75-1577

[6] Disanto G(2013)Development and validation of a claims-based prediction model for COPD severity Respir med 107 1568-1300

[7] Berlanga AJ(2015)Developing a stroke severity index based on administrative data was feasible using data mining techniques J Clin Epidemiol 68 1292-1656

[8] Handel AE(2013)Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis Curr med res Opin 29 1647-1471

[9] Para AE(2014)Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study PLoS One 9 e88472-1039

[10] Burrell AM(2014)Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis Curr med res Opin 30 1461-471